InMed Pharmaceuticals Inc. (INM)

CA — Healthcare Sector
Peers: QNRX  ALLR  KRBP  VRAX  BDRX  ICU  VIRI  ZVSA  SONN  REVB  PALI  DRUG  TNXP  IMMX  PHIO  ATNF  NAVB  SGTX  NBY  GOVX 

Automate Your Wheel Strategy on INM

With Tiblio's Option Bot, you can configure your own wheel strategy including INM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol INM
  • Rev/Share 216.7784
  • Book/Share 640.6659
  • PB 0.0049
  • Debt/Equity 0.0597
  • CurrentRatio 3.4857
  • ROIC -0.5666

 

  • MktCap 3814705.0
  • FreeCF/Share -713.0155
  • PFCF -0.0005
  • PE -0.0054
  • Debt/Assets 0.0452
  • DivYield 0
  • ROE -1.9289

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 5
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About InMed Pharmaceuticals Inc. (INM)

  • IPO Date 2014-05-05
  • Website https://www.inmedpharma.com
  • Industry Biotechnology
  • CEO Mr. Eric A. Adams B.S. Chem., M.I.B.
  • Employees 13
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.